![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Trial Updates on Zynlonta Combinations for DLBCL
Loncastuximab tesirine (Zynlonta by ADC Therapeutics) is an FDA-approved third-line treatment for people with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
This treatment is part of a drug class known as an antibody-drug conjugate (ADC) and is administered via intravenous infusion (IV). It targets the CD19 protein on the surface of cancer cells. Once attached, Zynlonta delivers chemotherapy directly into the cancer cell, leading to its destruction.
A clinical trial called the LOTIS-7 study is combining Zynlonta with various bispecific antibodies. A second part of the trial explores using Zynlonta as a second-line treatment for DLBCL, expanding its therapeutic potential.
Read insights from the LOTIS-7 trial below and learn how to review your eligibility to join the study.
LOTIS-7 Study: Zynlonta Combinations and Moving to a Second-Line Treatment for DLBCL
Part 1 of the LOTIS-7 trial evaluated different doses of Zynlonta as a third-line treatment for relapsed/refractory DLBCL in various combinations, such as with bispecific antibodies glofitamab (Columvi, Genentech) or mosunetuzumab (Lunsumio, Genentech), and with another antibody-drug conjugate called polatuzumab vedotin (Polivy, Genentech).
Results from this portion of the study were encouraging, showing that the side effects patients experienced were manageable, with little to no mild cytokine release syndrome (CRS, an inflammatory reaction that causes mild symptoms like fever) and no brain-related side effects (such as a common neurological effect known as ICANS). Researchers also saw that the treatment combinations showed anti-cancer activity against DLBCL cells.
Part 2 of the LOTIS-7 trial is now underway, evaluating Zynlonta in combination with glofitamab as a second-line therapy for individuals with DLBCL. This is an exciting development, as it could potentially move Zynlonta earlier in a patient’s treatment. Right now, it is currently FDA-approved only as a third-line DLBCL therapy.
If you are interested in joining the LOTIS-7 study, click here to review your eligibility. The trial has various recruiting locations in the United States, Belgium, Czechia, Italy, Spain, and the United Kingdom.
To learn more about clinical trials in general, click here.
Additional centers are testing the use of Zynlonta by itself and in other combinations. We will continue to share relevant results about these trials with you!
Summary
Zynlonta represents a promising treatment option for individuals with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Ongoing studies like the LOTIS-7 trial are exploring its potential as a second-line therapy, which could expand its availability to patients earlier in their treatment path. If you are interested in learning more or participating in a clinical trial, explore the opportunities available and consult with your DLBCL specialist about your eligibility.
Continue Reading DLBCL News
Click the button below to keep reading news about diffuse large B-cell lymphoma (DLBCL).
Sources:
Loncastuximab tesirine (Zynlonta by ADC Therapeutics) is an FDA-approved third-line treatment for people with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
This treatment is part of a drug class known as an antibody-drug conjugate (ADC) and is administered via intravenous infusion (IV). It targets the CD19 protein on the surface of cancer cells. Once attached, Zynlonta delivers chemotherapy directly into the cancer cell, leading to its destruction.
A clinical trial called the LOTIS-7 study is combining Zynlonta with various bispecific antibodies. A second part of the trial explores using Zynlonta as a second-line treatment for DLBCL, expanding its therapeutic potential.
Read insights from the LOTIS-7 trial below and learn how to review your eligibility to join the study.
LOTIS-7 Study: Zynlonta Combinations and Moving to a Second-Line Treatment for DLBCL
Part 1 of the LOTIS-7 trial evaluated different doses of Zynlonta as a third-line treatment for relapsed/refractory DLBCL in various combinations, such as with bispecific antibodies glofitamab (Columvi, Genentech) or mosunetuzumab (Lunsumio, Genentech), and with another antibody-drug conjugate called polatuzumab vedotin (Polivy, Genentech).
Results from this portion of the study were encouraging, showing that the side effects patients experienced were manageable, with little to no mild cytokine release syndrome (CRS, an inflammatory reaction that causes mild symptoms like fever) and no brain-related side effects (such as a common neurological effect known as ICANS). Researchers also saw that the treatment combinations showed anti-cancer activity against DLBCL cells.
Part 2 of the LOTIS-7 trial is now underway, evaluating Zynlonta in combination with glofitamab as a second-line therapy for individuals with DLBCL. This is an exciting development, as it could potentially move Zynlonta earlier in a patient’s treatment. Right now, it is currently FDA-approved only as a third-line DLBCL therapy.
If you are interested in joining the LOTIS-7 study, click here to review your eligibility. The trial has various recruiting locations in the United States, Belgium, Czechia, Italy, Spain, and the United Kingdom.
To learn more about clinical trials in general, click here.
Additional centers are testing the use of Zynlonta by itself and in other combinations. We will continue to share relevant results about these trials with you!
Summary
Zynlonta represents a promising treatment option for individuals with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Ongoing studies like the LOTIS-7 trial are exploring its potential as a second-line therapy, which could expand its availability to patients earlier in their treatment path. If you are interested in learning more or participating in a clinical trial, explore the opportunities available and consult with your DLBCL specialist about your eligibility.
Continue Reading DLBCL News
Click the button below to keep reading news about diffuse large B-cell lymphoma (DLBCL).
Sources:
about the author
Megan Heaps
Megan joined HealthTree in 2022. She enjoys helping patients and their care partners understand the various aspects of the cancer. This understanding enables them to better advocate for themselves and improve their treatment outcomes.
More on Clinical Trials
Trending Articles
Stay Informed. Get the Support You Need for Diffuse Large B Cell Lymphoma.
By subscribing to the Healthtree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.
Follow Us
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2025 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811